Vidarabine, an anti-herpes agent, improves Porphyromonas gingivalis lipopolysaccharide-induced cardiac dysfunction in mice

J Physiol Sci. 2023 Aug 9;73(1):18. doi: 10.1186/s12576-023-00873-5.

Abstract

In this work, we examined the involvement of type 5 adenylyl cyclase (AC5) in cardiac dysfunction induced in mice given Porphyromonas gingivalis lipopolysaccharide (PG-LPS) at a dose equivalent to the circulating levels in periodontitis (PD) patients. Cardiac function was significantly decreased in mice given PG-LPS compared to the control, but treatment for 1 week with the AC5 inhibitor vidarabine ameliorated the dysfunction. Cardiac fibrosis and myocyte apoptosis were significantly increased in the PG-LPS group, but vidarabine blocked these changes. The PG-LPS-induced cardiac dysfunction was associated with activation of cyclic AMP/Ca2+-calmodulin-dependent protein kinase II signaling and increased phospholamban phosphorylation at threonine 17. These results suggest that pharmacological AC5 inhibition may be a promising approach to treat PD-associated cardiovascular disease.

Keywords: Adenylyl cyclase; Apoptosis; Fibrosis; Heart failure; Periodontitis; Signal transduction; β-Adrenergic signaling.

MeSH terms

  • Animals
  • Cardiomyopathies*
  • Heart
  • Lipopolysaccharides / toxicity
  • Mice
  • Porphyromonas gingivalis
  • Vidarabine*

Substances

  • Vidarabine
  • Lipopolysaccharides